Immunome Inc (IMNM NASDAQ) stock market data APIs
$20.42
-0.48(-2.4%)
as of November 3, 2026
Try our APIs with
free plan!
Immunome Inc Financial Data Overview
Price chart is built with
Anychart
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Prev. Close
20.42
Open
19.9406
High
20.4905
Low
19.6718
52 wk Range
14.64-30.06
Market Cap
2 312 M
Shares Outstanding
118 M
Beta
2.662
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunome Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunome Inc data using free add-ons & libraries
Get Immunome Inc Fundamental Data
Immunome Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -257 687 008
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -0.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunome Inc News
New
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
CHICAGO, October 21, 2026--(BUSINESS WIRE)--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm's continued expansi...
What This Immunome Sale Means a Day Before a Big FDA Milestone
Key Points An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider's total equity hol...
What This Immunome Sale Means a Day Before a Big FDA Milestone
Isaac Barchas, a director at Immunome, Inc. (NASDAQ:IMNM), executed a sale of 100,000 shares in a transaction disclosed in a recent SEC Form 4 filing. Transaction summary Metric Value Transaction va...
Immunome Stock Up 32% in a Month: Here's What You Should Know
Shares of Immunome IMNM have witnessed a sharp increase over the past month, primarily driven by the growing investor confidence in the company's lead asset, varegacestat, and broader clinical progres...
Get Immunome Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.